Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Veryan Receives CE Mark Approval for BioMimics 3D™ Stent

Published: Monday, November 19, 2012
Last Updated: Monday, November 19, 2012
Bookmark and Share
A novel platform technology designed for treating the major arteries of the leg in patients with PAD.

Imperial Innovations Group plc has announced that portfolio company Veryan, a vascular disease specialist, has received CE Mark approval for the BioMimics 3D™ Stent.

Its unique design mimics the natural helical geometry of the human vascular system, improving blood flow and reducing kinking and deformation of the stent during movement of the leg, to protect the vessel from damage.

CE Mark approval follows on from meeting the primary endpoints of the MIMICS study, a prospective randomized controlled trial comparing the safety and efficacy of the BioMimics 3D stent with a standard nitinol stent.

Follow up assessments of patients involved in the trial have already demonstrated an excellent safety profile and clinical performance at both 6 and 12 months, and will continue for two years.

Prevalence of PAD is increasing due to an aging population with a rising incidence of risk factors such as diabetes and obesity.

The multibillion pound global PAD market represents a major opportunity for innovative products enabling minimally invasive endovascular intervention.

Veryan is planning to commercialize the BioMimics 3D stent system both in Europe and other global markets where CE Mark approval may expedite the registration process.

Veryan completed a £5 million funding round in October 2011, co-led by Innovations and Seroba Kernal Life Sciences, to progress the company towards a clinical study in the USA to achieve FDA approval. To date, Innovations has invested £9.1 million and has a 46.8% stake in the business.

Susan Searle, Chief Executive Officer, Imperial Innovations, said: “We are delighted that Veryan, one of our leading assets, has achieved this key milestone in the development of its technology. The results of the MIMICS trial are promising and the CE Mark is an important step towards commercialization for Veryan.”

Chas Taylor, Chief Executive Officer of Veryan, said: “CE Mark is an important milestone for Veryan. In conjunction with the encouraging data from the MIMICS study recently presented at the prestigious VIVA conference in Las Vegas, we are greatly encouraged that the unique geometry of the BioMimics 3D stent will be highly competitive against conventional straight nitinol stents. We believe the ability to take this differentiated platform technology to market may contribute significantly to fulfilling the need for more durable clinical outcomes in patients with PAD undergoing endovascular intervention.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Innovations Leads £3 Million Investment in Abingdon Health
Company has appointed Chris Yates as CEO.
Tuesday, July 07, 2015
Cell Medica Announces Start of Commercial Cell Therapy Manufacture
Manufacturing will be focused on Cytovir™ CMV for the treatment of patients with CMV infections.
Friday, February 20, 2015
Imperial Innovations Leads £18 Million Series B Funding Round in Veryan
Innovations will hold a 47.8% stake in the issued share capital of Veryan.
Saturday, January 17, 2015
MISSION Therapeutics Receives £20m Series B Funding
Financing round will enable MISSION to advance its programmes for the treatment of cancers.
Monday, December 09, 2013
Circassia’s Grass Allergy Treatment Achieves Significant Symptom Reduction
Circassia has achieved successful results from a large phase II clinical study of its grass allergy treatment.
Tuesday, October 08, 2013
Cell Medica Opens Commercial Manufacturing Facility in Germany
Commercial launch of Cytovir CMV is planned for early 2014.
Thursday, September 26, 2013
Innovations Invests in £17 Million Funding Round for Portfolio Company, Cell Medica
Cell Medica continue to develop immune reconstitution cell therapies in Europe and to launch new operations in US.
Tuesday, July 24, 2012
Innovations Leads £3m Funding Round in Abingdon Health
Company invests £2m in this round.
Tuesday, March 27, 2012
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with polycystic ovary syndrome (PCOS), a leading cause of infertility, may produce excess adrenal hormones.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
How Cancer Spreads in the Body
Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London.
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!